Xencor (NASDAQ:XNCR) Announces Earnings Results, Beats Estimates By $0.27 EPS

Xencor (NASDAQ:XNCR) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.27, Briefing.com reports. Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same quarter in the prior year, the company posted ($0.40) EPS. Xencor’s quarterly revenue was down 81.9% on a year-over-year basis.

Xencor Stock Up 2.5 %

Shares of XNCR traded up $0.57 during mid-day trading on Thursday, reaching $23.25. The company’s stock had a trading volume of 357,593 shares, compared to its average volume of 596,188. The company’s 50 day moving average is $20.21 and its 200 day moving average is $20.21. The stock has a market cap of $1.63 billion, a PE ratio of -7.88 and a beta of 0.66. Xencor has a 12-month low of $15.31 and a 12-month high of $26.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92.

Wall Street Analyst Weigh In

XNCR has been the subject of a number of analyst reports. Royal Bank of Canada increased their target price on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. BMO Capital Markets reissued an “outperform” rating and set a $32.00 target price on shares of Xencor in a research report on Tuesday, August 6th. JPMorgan Chase & Co. raised their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Wedbush reissued an “outperform” rating and set a $38.00 price objective on shares of Xencor in a report on Thursday. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xencor currently has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.